|drug466||COVID-19 Specific T Cell derived exosomes (CSTC-Exo) Wiki||1.00|
|drug2309||Standard Public Health measures Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).
Description: Incidence of secondary PCR confirmed symptomatic Covid-19 episodes among contacts after high risk PCR+ exposureMeasure: Study 1- Clinical and virological outcome in exposed contacts Time: Up to 14 days after start of treatment
Description: Incidence of symptomatically compatible or a PCR-positive result regardless of symptomsMeasure: Study 1- Transmission of SARS-CoV-2 in exposed contacts Time: Up to 14 days after start of treatment
Description: Reduction of viral RNA load in nasopharyngeal swabs at days 3, and 7 after treatment start.Measure: Study 2- Virological outcome in index cases Time: Up to 7 days after start of treatment
Description: Time from randomization to complete resolution of symptoms at an extended 28-days follow-Measure: Study 2- Clinical outcome in index cases Time: Up to 28 days after start of treatment